Pacific Center for Financial Services’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Pacific Center for Financial Services’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$690K	Sell	4,362 -14	-0.3%	-$1.89K	0.15%	51
2026 Q1	$559K	Buy	4,376 +16	+0.4%	+$2K	0.14%	55
2025 Q4	$437K	Hold	4,360	–	–	0.11%	58
2025 Q3	$437K	Hold	4,360	–	–	0.11%	58
2025 Q2	$362K	Hold	4,360	–	–	0.1%	60
2025 Q1	$354K	Hold	4,360	–	–	0.09%	61
2024 Q4	$393K	Hold	4,360	–	–	0.1%	55
2024 Q3	$431K	Hold	4,360	–	–	0.11%	53
2024 Q2	$404K	Buy	4,360 +1	+0%	+$90	0.11%	55
2024 Q1	$414K	Buy	4,359 +118	+3%	+$10.9K	0.12%	54
2023 Q4	$379K	Hold	4,241	–	–	0.12%	50
2023 Q3	$310K	Sell	4,241 -849	-17%	-$67.8K	0.11%	59
2023 Q2	$423K	Hold	5,090	–	–	0.14%	48
2023 Q1	$388K	Buy	+5,090	New	+$422K	0.13%	53
2022 Q3	$404K	Hold	5,090	–	–	0.16%	47
2022 Q2	$378K	Hold	5,090	–	–	0.16%	51
2022 Q1	$457K	Sell	5,090 -681	-12%	-$62.9K	0.16%	45
2021 Q4	$646K	Buy	5,771 +533	+10%	+$64.3K	0.26%	35
2021 Q3	$658K	Buy	5,238 +143	+3%	+$18.4K	0.29%	32
2021 Q2	$690K	Buy	5,095 +90	+2%	+$11.8K	0.3%	29
2021 Q1	$679K	Buy	5,005 +52	+1%	+$7.79K	0.32%	28
2020 Q4	$697K	Buy	4,953 +227	+5%	+$29.1K	0.26%	28
2020 Q3	$527K	Buy	4,726 +1	+0%	+$112	0.22%	30
2020 Q2	$529K	Buy	4,725 +73	+2%	+$7.19K	0.26%	29
2020 Q1	$360K	Buy	4,652 +63	+1%	+$5.58K	0.23%	29
2019 Q4	$436K	Buy	4,589 +134	+3%	+$11.6K	0.19%	32
2019 Q3	$340K	Buy	4,455 +85	+2%	+$7.06K	0.17%	36
2019 Q2	$383K	Sell	4,370 -164	-4%	-$14K	0.2%	31
2019 Q1	$410K	Hold	4,534	–	–	0.22%	29
2018 Q4	$325K	Hold	4,534	–	–	0.17%	31
2018 Q3	$435K	Hold	4,534	–	–	0.21%	28
2018 Q2	$432K	Sell	4,534 -813	-15%	-$74.7K	0.25%	28
2018 Q1	$469K	Hold	5,347	–	–	0.29%	27
2017 Q4	$454K	Sell	5,347 -118	-2%	-$9.88K	0.28%	27
2017 Q3	$473K	Buy	5,465 +2	+0%	+$160	0.3%	25
2017 Q2	$422K	Buy	5,463 +661	+14%	+$46.9K	0.28%	27
2017 Q1	$333K	Sell	4,802 -655	-12%	-$44K	0.23%	31
2016 Q4	$323K	Buy	+5,457	New	+$337K	0.25%	33

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

Pacific Center for Financial Services's XBI Position: Q2 2026 in Review

Pacific Center for Financial Services reduced its State Street SPDR S&P Biotech ETF (XBI) stake by 0.32% in Q2 2026, selling an estimated $1.89K and leaving 4,362 shares worth $690K. The position accounts for 0.15% of the portfolio, ranked #51.

Pacific Center for Financial Services first reported a position in XBI in Q4 2016 and has held it in 38 quarters since. The position peaked at $697K in Q4 2020. 933 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

Pacific Center for Financial Services held 4,362 shares of State Street SPDR S&P Biotech ETF worth $690K as of Q2 2026.
Pacific Center for Financial Services sold 14 State Street SPDR S&P Biotech ETF shares in Q2 2026, an estimated $1.89K.
State Street SPDR S&P Biotech ETF made up 0.15% of Pacific Center for Financial Services's portfolio in Q2 2026, its #51 holding.
Pacific Center for Financial Services first reported a position in State Street SPDR S&P Biotech ETF in Q4 2016 and has held it in 38 quarters since.
Pacific Center for Financial Services's State Street SPDR S&P Biotech ETF position peaked at $697K in Q4 2020.
933 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on Pacific Center for Financial Services's 13F filing for Q2 2026, filed 5 Aug 2026.